HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of ranibizumab combined with photocoagulation for diabetic retinopathy: A meta-analysis study.

AbstractBACKGROUND:
Ranibizumab addition may benefit to improve the efficacy in patients with diabetic retinopathy than only photocoagulation, and this meta-analysis aims to explore the impact of ranibizumab addition on efficacy for diabetic retinopathy.
METHODS:
PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials assessing the effect of ranibizumab addition on patients with diabetic retinopathy for this meta-analysis.
RESULTS:
Six randomized controlled trials were finally included in the meta-analysis. Overall, compared with control intervention for diabetic retinopathy, ranibizumab addition showed significantly increased number of neovascularization area reduction (OR = 4.20; 95% CI = 1.47-12.02; P = .007) and reduced fluorescein leakage (MD = -2.53; 95% CI = -3.31 to -1.75; P < .00001), but showed no obvious impact on neovascularization area (MD = -1.80; 95% CI = -3.68 to 0.08; P = .06), photocoagulation retreatment (OR = 1.03; 95% CI = 0.47-2.27; P = .94) or adverse events (OR = 1.45; 95% CI = 0.49-4.29; P = .50).
CONCLUSIONS:
Ranibizumab combined with photocoagulation is effective to improve efficacy for diabetic retinopathy.
AuthorsHongli Yin, Senquan Zhong
JournalMedicine (Medicine (Baltimore)) Vol. 102 Issue 31 Pg. e34170 (Aug 04 2023) ISSN: 1536-5964 [Electronic] United States
PMID37543834 (Publication Type: Systematic Review, Meta-Analysis, Journal Article)
CopyrightCopyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Chemical References
  • Ranibizumab
  • Angiogenesis Inhibitors
  • Bevacizumab
  • Vascular Endothelial Growth Factor A
Topics
  • Humans
  • Ranibizumab (therapeutic use)
  • Diabetic Retinopathy (complications, drug therapy, surgery)
  • Angiogenesis Inhibitors (therapeutic use)
  • Bevacizumab (therapeutic use)
  • Vascular Endothelial Growth Factor A (therapeutic use)
  • Laser Coagulation
  • Intravitreal Injections
  • Diabetes Mellitus (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: